drug
(meropenem + vaborbactam)
Marketedupdated 5mo agoby A. Menarini Industrie Farmaceutiche Riunite Srl
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying (meropenem + vaborbactam)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 29, 2027
333 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- May 20, 2039method-of-use (U-3421)US 12533342
- Apr 6, 2039method-of-use (U-3421)US 11376237
- Jan 8, 2038method-of-use (U-3421)US 12478606
- Aug 29, 2031compositionUS 86801364.9y
- Aug 8, 2031formulationUS 101728744.9y
- Aug 8, 2031method-of-use (U-2490)US 101830344.9y
- Aug 8, 2031method-of-use (U-2490)US 105616754.9y
- Aug 8, 2031method-of-use (U-3128)US 110072064.9y
- Aug 8, 2031compositionUS 121717724.9y
- Aug 8, 2031method-of-use (U-2120)US 96940254.9y
FDA exclusivities (2)
- Aug 29, 2027GAINGAIN Antibiotic (5y)333d
- Aug 29, 2022NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 54m ago
Found something off?
comments(0)
5-min edit window · permanent after that